Lightlake Therapeutics, Inc.
| OTC Markets: LLTP
Lightlake Therapeutics, Inc. is an early stage biopharmaceutical company and develops pharmaceutical solutions to obesity and eating disorders. The company focuses on completing the clinical trials of an Opioid antagonist-based nasal spray for the treatment of Binge Eating Disorder. Naloxone and other Opioid antagonists have been tested for years for different applications including excessive drug use and excessive alcohol consumption. It conducts Phase II clinical trials in Helsinki, Finland to investigate the use of the Opioid antagonist naloxone intra-nasally as a treatment for Binge Eating Disorder. Lightlake Therapeutics was founded on June 21, 2005 and is headquartered in London, the United Kingdom.